Pericardial effusion under nivolumab: case-reports and review of the literature

BACKGROUND: Nivolumab, a programmed death-1 (PD-1) inhibitor, is an immune checkpoint inhibitor particularly used in the treatment of malignant melanoma, non-small cell lung cancer and renal cell carcinoma. Immune-related adverse events are frequent under immunotherapies. Cardiotoxic side effects, i...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Immunother Cancer
Hlavní autoři: Anastasia, Saade, Audrey, Mansuet-Lupo, Jennifer, Arrondeau, Constance, Thibault, Mariana, Mirabel, François, Goldwasser, Stéphane, Oudard, Laurence, Weiss
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6798500/
https://ncbi.nlm.nih.gov/pubmed/31627742
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0760-4
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky